Safety and Efficacy of Glucagon-like Peptide 1 Receptor Agonists in Patients With Cirrhosis

被引：5
|
作者：
Morris, Sean M. [1 ]
Armstrong, Matthew J. [1 ,2 ]
Newsome, Philip N. [1 ,2 ]
机构：
[1] Univ Birmingham, Inst Immunol & Immunotherapy, Ctr Liver & Gastrointestinal Res, Birmingham, W Midlands, England
[2] Univ Birmingham, Univ Hosp Birmingham NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, Birmingham, W Midlands, England
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2022年 / 20卷 / 06期
关键词：
D O I：
10.1016/j.cgh.2021.09.023
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1220 / 1222
页数：3
相关论文
共 50 条
  • [31] Summary for Patients: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
    不详
    ANNALS OF INTERNAL MEDICINE, 2025,
  • [32] Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis
    Ryan, Paul M.
    Seltzer, Sean
    Hayward, Nathaniel E.
    Rodriguez, David Avelar
    Sless, Ryan T.
    Hawkes, Colin P.
    JOURNAL OF PEDIATRICS, 2021, 236 : 137 - 147
  • [33] Are glucagon-like peptide-1 receptor agonists the functional cure for patients with metabolic dysfunction-associated cirrhosis?
    Dajti, Elton
    Rodrigues, Susana G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (10) : 1286 - 1287
  • [34] Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
    Handelsman, Yehuda
    Wyne, Kathleen
    Cannon, Anthony
    Shannon, Michael
    Schneider, Doron
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (09): : S14 - S29
  • [35] THE EFFICACY OF TREATMENT WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN CHRONIC DIALYSIS PATIENTS WITH DIABETES MELLITUS
    Takeda, Kazuhito
    Toyonaga, Jiro
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [36] Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
    Raccah, Denis
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (02) : 227 - 236
  • [37] Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
    Harris, Kira B.
    McCarty, Delilah J.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (01) : 3 - 18
  • [38] Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!
    Patoulias, Dimitrios
    Caprio, Massimiliano
    Stoian, Anca Pantea
    Rizzo, Manfredi
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (09) : 763 - 765
  • [39] Long-Acting Glucagon-Like Peptide 1 Receptor Agonists A review of their efficacy and tolerability
    Garber, Alan J.
    DIABETES CARE, 2011, 34 : S279 - S284
  • [40] A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients
    Carlucci, Philip
    Cohen, Brooke
    Saxena, Amit
    Belmont, H. Michael
    Masson, Mala
    Gold, Heather
    Buyon, Jill
    Izmirly, Peter
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3026 - 3029
12345